Seeing Is Believing
Currently out of the existing stock ratings of Mark Breidenbach, 123 are a BUY (99.19%), 1 are a HOLD (0.81%).
Analyst Mark Breidenbach works with a stock forecast success ratio of 36.71% fulfilled within 184.64 days on average. Previously, Mark Breidenbach worked at OPPENHEIMER.
Mark Breidenbach’s has documented 240 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on EPIX, ESSA Pharma at 13-Dec-2023.
Analyst best performing recommendations are on KDMN (KADMON HOLDINGS).
The best stock recommendation documented was for ARVN (ARVINAS) at 12/14/2020. The price target of $80 was fulfilled within 8 days with a profit of $21.62 (37.03%) receiving and performance score of 46.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
8
$3.54 (79.37%)
9
1 months 1 days ago
0/3 (0%)
$2.86 (55.64%)
Buy
10
$5.54 (124.22%)
12
2 months 9 days ago
1/7 (14.29%)
$6.91 (223.62%)
28
Buy
10
$5.54 (124.22%)
12
2 months 9 days ago
0/5 (0%)
$6.91 (223.62%)
Buy
18
2 months 20 days ago
2/9 (22.22%)
$12.2 (210.34%)
94
Hold
35
2 months 23 days ago
1/2 (50%)
$19.71 (128.91%)
6
Which stock is Mark Breidenbach is most bullish on?
What Year was the first public recommendation made by Mark Breidenbach?